Medication info
Umero Tablets 20/20mg

Umero Tablets 20/20mg

Prescription medicationTabletOral
Ingredient · strength
Olmesartan Medoxomil›20mg / 1 tabletRosuvastatin Calcium›20.8mg / 1 tablet
Manufacturer / importer
Kips Biopharma Co., Ltd.
Appearance
White or pale yellow round film-coated tablets
Packaging
30 tablets/box[30 tablets (10 tablets/Alu-Alu) x 3]
Approval status
Active

MFDS item code 202003953 · Approved 2020.05.28

Summary

Main use
Treatment of dyslipidemia and hypertension, inhibition of atherosclerotic progression and cardiovascular disease risk
Who takes it
Adults · Children
Adult dose
This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10 mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40 mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is required when this medicine is administered to elderly patients aged 65 years or older. No overall differences in efficacy or safety have been observed between elderly and younger patients; however, the possibility of a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20 mg once daily. 4. Patients with hepatic impairment No dose adjustment is required for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, and the dose may be increased to a maximum of 20 mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, the treatment goal, and the patient's response, at intervals of 4 weeks or longer; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients No dose adjustment is required. 3. Patients with renal impairment No dose adjustment is required for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.
Child dose
Safety and efficacy in children under 18 years of age have not been established.

Ingredients

Manufacturer
Kips Biopharma Co., Ltd.

Efficacy & effects

Treatment of dyslipidemia and hypertension, inhibition of atherosclerotic progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • elevated high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary heart disease
View approved original text

This medication is used for patients who require concomitant therapy with olmesartan medoxomil and rosuvastatin. Olmesartan medoxomil helps to treat essential hypertension. Rosuvastatin is used as an adjunct therapy for patients with hypercholesterolemia or hyperlipidemia when diet and exercise are insufficient. Additionally, it contributes to slowing the progression of atherosclerosis and reducing the risks of stroke, myocardial infarction, and vascular interventions in patients at high risk of cardiovascular diseases. This medication is used to improve cardiovascular health through the control of hypertension and cholesterol.

How to take

Adult dose

This medicine is for adults only. The dose should be individualized for each patient based on the effects and tolerability of each component, olmesartan medoxomil and rosuvastatin. ◆ Olmesartan medoxomil 1. Adults The recommended initial dose is 10 mg once daily, with or without food. If blood pressure is not adequately controlled at this dose, the dose may be increased to 20 mg once daily. If further blood pressure reduction is required, the dose may be increased to a maximum of 40 mg once daily. The blood pressure-lowering effect appears within 2 weeks after starting treatment and reaches its maximum after approximately 8 weeks. If blood pressure is not controlled with this medicine alone, it may be administered concomitantly with a thiazide diuretic such as hydrochlorothiazide. To improve adherence, it is recommended that the medicine be taken at the same time each day, if possible (e.g., in the morning). In patients who may have intravascular volume depletion (e.g., patients receiving diuretics, especially those with renal impairment), it is recommended to start treatment at a low dose while closely monitoring their condition. 2. Elderly patients No dose adjustment is required when this medicine is administered to elderly patients aged 65 years or older. No overall differences in efficacy or safety have been observed between elderly and younger patients; however, the possibility of a more sensitive response in some elderly patients cannot be ruled out. 3. Patients with renal impairment The maximum dose for patients with mild to moderate renal impairment (creatinine clearance 30-60mL/min) is 20 mg once daily. 4. Patients with hepatic impairment No dose adjustment is required for patients with mild hepatic impairment. The recommended initial dose for patients with moderate hepatic impairment is 10 mg once daily, and the dose may be increased to a maximum of 20 mg once daily. Use in patients with severe hepatic impairment is not recommended because there is no experience with its use in these patients. ◆ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with this medicine and continue it throughout the treatment period. This medicine may be taken at any time of day, with or without food. The initial dose is 5 mg once daily. If a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be adjusted as appropriate according to LDL cholesterol levels, the treatment goal, and the patient's response, at intervals of 4 weeks or longer; the dose may be increased to a maximum of 20 mg once daily. 2. Elderly patients No dose adjustment is required. 3. Patients with renal impairment No dose adjustment is required for patients with mild to moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering 20 mg of this medicine to patients with moderate renal impairment. 4. Patients with hepatic impairment No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but an increase was observed in patients with a Child-Pugh score of 8 or 9. Renal function tests should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer this medicine to patients with active liver disease. 5. Race Because systemic exposure to this medicine is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of the 40 mg dose of this medicine is contraindicated in some of these patients. Patients taking olmesartan medoxomil and rosuvastatin concomitantly may switch to this medicine (a combination product containing the same amounts of each active ingredient) for convenience.

Child dose

Safety and efficacy in children under 18 years of age have not been established.

Precautions

This medication can cause serious harm to the fetus and newborn if taken during the second and third trimesters of pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Individuals allergic to this medication or its components should not take it, and women who are pregnant or may become pregnant, as well as nursing mothers, should not use it. Patients with severely impaired renal function, those undergoing renal dialysis, severe liver dysfunction, and those with bile duct obstruction should not take this medication. Caution should be taken as the risk of muscle damage may increase in patients with muscle-related diseases or in those using certain medications concomitantly. This medication contains lactose, so patients with genetic issues such as lactose intolerance or galactose intolerance should avoid it. Patients with low blood pressure or insufficient body salt may experience hypotension during the initial doses, and should monitor their condition carefully. Patients with impaired renal function or renal transplant recipients should have their renal function and electrolyte status checked periodically through blood tests. Due to the risk of hyperkalemia, it is important to regularly monitor blood potassium levels. Patients with a history of excessive alcohol intake or liver diseases should undergo regular liver function tests while taking this medication. If symptoms like muscle pain or weakness occur, inform the doctor immediately and undergo necessary tests; in severe cases, usage should be discontinued. This medication may interact with other drugs, so inform a healthcare provider about any other medications being taken. Women who are pregnant or planning to become pregnant must consult a doctor and use appropriate contraception. Safety and effectiveness in children or adolescents under 18 have not been established, so use should be avoided. In case of overdose, symptoms such as hypotension or palpitations may occur, and immediate medical attention must be sought. Store this medication out of reach of children, and it is advisable not to transfer it to another container.

Side effects

Increased ALT, increased AST, increased blood creatinine, decreased creatinine clearance, headache, dizziness, sensory decrease, neuropathy, drowsiness, gastroesophageal reflux disease, constipation, dental caries, dyspepsia, gastric ulcer, gastritis, gastroenteritis, musculoskeletal stiffness, atrial fibrillation, hypoglycemia, chest pain, tooth extraction, chest discomfort, peripheral edema, vertigo, abdominal pain, nausea, palpitations, hypercholesterolemia, hyperlipidemia, hyperuricemia, arthralgia, arthritis, myalgia, rash, weakness, angioedema, anaphylactic reaction, vomiting, chronic malabsorption syndrome, intestinal vascular edema, rhabdomyolysis, hyperkalemia, acute kidney failure, hair loss, pruritus, urticaria, autoimmune hepatitis, dizziness (including positional dizziness), headache, palpitations, increased blood pressure, facial swelling, back pain, increased blood creatinine, diarrhea, cough, epistaxis, upper respiratory infection, asthma, hypersensitivity reaction including angioedema, diabetes, headache, dizziness, constipation, nausea, abdominal pain, pancreatitis, pruritus, rash, urticaria, myalgia, myopathy, rhabdomyolysis, weakness, polyneuropathy, amnesia, peripheral neuropathy, cough, dyspnea, diarrhea, thrombocytopenia, jaundice, hepatitis, transaminase elevation, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms, lupus-like syndrome, muscle rupture, arthralgia, immune-mediated necrotizing myopathy, hematuria, edema, depression, sleep disorders, interstitial lung disease, sexual dysfunction, gynecomastia, fatal and non-fatal liver failure, cognitive impairment, severe muscle weakness, ophthalmoplegia

Not everyone experiences these, and they can vary from person to person.

Storage

This medication may be sensitive to air or moisture, so it should be stored in a tightly closed container. It is recommended to keep the storage temperature between 1 and 30 degrees Celsius at room temperature to safely maintain the medication's effectiveness.

Appearance and packaging

Appearance

White or pale yellow round film-coated tablets

Package unit

30 tablets/box[30 tablets (10 tablets/Alu-Alu) x 3]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.